Adage Capital Partners
IRD

Adage Capital Partners’s Opus Genetics IRD Stock Holding History

Adage Capital Partners’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4M Buy
6,029,775
+4,924,779
+446% +$17M 0.04% 384
2025
Q4 		$2.22M Buy
1,104,996
+150,000
+16% +$305K ﹤0.01% 829
2025
Q3 		$1.58M Buy
+954,996
New +$1.19M ﹤0.01% 820

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Adage Capital Partners's IRD Position: Q1 2026 in Review

Adage Capital Partners increased its Opus Genetics (IRD) stake by 446% in Q1 2026, buying an estimated $17M and bringing the position to 6,029,775 shares worth $27.4M. The position accounts for 0.04% of the portfolio, ranked #384.

Adage Capital Partners first reported a position in IRD in Q3 2025 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Adage Capital Partners held 6,029,775 shares of Opus Genetics worth $27.4M as of Q1 2026.
  • Adage Capital Partners bought 4,924,779 Opus Genetics shares in Q1 2026, an estimated $17M.
  • Opus Genetics made up 0.04% of Adage Capital Partners's portfolio in Q1 2026, its #384 holding.
  • Adage Capital Partners first reported a position in Opus Genetics in Q3 2025 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.